Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1471 to 1485 of 2185 results for guidelines

  1. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA786

  2. Is obesity an independent risk factor for perinatal morbidity and mortality?

    the woman's preference and obstetric indications in line with the NICE guideline on intrapartum care for health women and babies . There...

    Research recommendation
    Published
    16 August 2019

  3. Organisation of care:- What is the clinical and cost effectiveness of alternative approaches to organising primary care compared with usual care for people with multimorbidity?

    Any explanatory notes(if applicable) Why this is important:- The guideline committee felt that primary care was well suited to managing...

    Research recommendation
    Published
    18 October 2016

  4. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    and cost effectiveness. The cost-effectiveness model developed for this guideline combined evidence of clinical effectiveness, costs and...

    Research recommendation
    Published
    9 June 2015

  5. What are the information and support needs of parents and carers with babies on parenteral nutrition?

    as encouraging shared decision making, are covered in the NICE clinical guideline on patient experience in adult NHS services. Given...

    Research recommendation
    Published
    17 March 2020

  6. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  7. Coronary revascularisation: Cangrelor (ESNM63)

    Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 November 2015

  8. What training, support or interventions help to reduce caring-related accidents or incidents?

    are included in the psychological and emotional support section of this guideline.By consensus, the committee also agreed to add some...

    Research recommendation
    Published
    10 February 2020

  9. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA537

  10. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  11. What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration of follow‑up, frequency of follow‑up appointments, the type of examination or blood tests, and the roles of primary and secondary care in follow‑up?

    committee agreed that the 2‑year follow‑up recommended in the previous guideline was conservative, and based on their expertise, people...

    Research recommendation
    Published
    25 October 2019

  12. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (HTG375)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

    HealthTech guidance
    Published
    26 June 2015
    View recommendations

    Sections for HTG375

  13. Optilume for anterior urethral strictures (MIB241)

    NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .

    Medtech innovation briefing
    Published
    5 January 2021

  14. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

    Medtech innovation briefing
    Published
    6 July 2021

  15. Sepsis (QS161)

    November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard